Mechanism of action of Crizotinib

Crizotinib is a kinase inhibitor, and Crizotinib is an inhibitor of receptor tyrosine kinases. The translocation can affect the ALK gene, resulting in the expression of an oncogenic fusion protein. ALKThe formation of fusion proteins results in activation and dysregulation of gene expression and signaling, which helps increase cell proliferation and survival in tumors that express these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines, and in cells expressing echinoderm microtubule-associated protein-like 4 Antitumor activity was demonstrated in mice with tumor xenografts of (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.

In vitro, crizotinib induces apoptosis and inhibits proliferation and ALK-mediated signaling in ALCLderived cell lines (containing NPM-ALK) at clinically achievable exposures. In vivo data obtained in an ALCL-derived mouse model showed complete tumor regression at a dose of 100 mg/kg once daily.

While taking crizotinib, patients will need blood tests to help monitor liver and kidney function, red and white blood cell counts, and, in some cases, electrolytes or blood sugar levels. These tests help track response to treatment and adjust a patient's medication dosage if needed. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.